GSK sells rare disease gene therapy portfolio – Financial Times
|
GSK sells rare disease gene therapy portfolio
Financial Times GlaxoSmithKline has offloaded its rare disease gene therapy portfolio to the biotechnology company Orchard Therapeutics, in exchange for a near-20 per cent stake in the two-year-old business. A sale of the rare disease unit had been mooted since last … |
